|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Report Highlights :
Publisher's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 16, 128, 33 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 46 and 14 molecules, respectively. Obesity.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/obesity-pipeline-review-h2-2016
Report Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001461478/sample
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
Abeome Corporation
Acylin Therapeutics Inc
Advinus Therapeutics Ltd
Aegis Therapeutics, LLC
Akron Molecules AG
Alize Pharma SAS
Amabiotics SAS
Amgen Inc.
Aoxing Pharmaceutical Company, Inc
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Athersys, Inc.
Biophytis SAS
BioRestorative Therapies, Inc.
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3 Jian, Inc
Carmot Therapeutics Inc
Chronos Therapeutics Limited
CohBar, Inc.
CoMentis, Inc.
Connexios Life Sciences Pvt. Ltd.
Corium International, Inc.
Daiichi Sankyo Company, Limited
Diabetica Limited
DiscoveryBiomed, Inc.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd.
FibroGen Inc
Galenea Corp.
Gila Therapeutics Inc
Gilead Sciences, Inc.
GlaxoSmithKline Plc
GTx, Inc.
HanAll Biopharma Co., Ltd.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hyundai Pharmaceutical Co., Ltd.
Immungenetics AG
Intarcia Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Ixchel Pharma, LLC
Jenrin Discovery, Inc.
Johnson & Johnson
Kowa Company, Ltd.
Lead Discovery Center GmbH
Leading BioSciences, Inc.
LEO Pharma A/S
LG Life Science LTD.
Lotus Pharmaceutical Co., Ltd.
M Pharmaceutical Inc.
Magnus Life Ltd
MAKScientific, LLC
MedImmune LLC
Merck & Co., Inc.
Mitochon Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
NeuroNano Pharma Inc
NGM Biopharmaceuticals, Inc.
NIBEC
Nordic Bioscience A/S
Novo Nordisk A/S
ObeTherapy Biotechnology
Ogeda SA
Omeros Corporation
OPKO Biologics Ltd
OPKO Health, Inc.
Orbis Biosciences Inc
Orexigen Therapeutics, Inc.
Pfizer Inc.
PharmaIN Corporation
Poxel SA
Progenra, Inc.
Prometheon Pharma, LLC
ReCyte Therapeutics, Inc.
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc.
Saniona AB
Sanofi
Selvita S.A.
Seoul Pharma Co., Ltd.
Shionogi & Co., Ltd.
Sinil Pharmaceutical Co., Ltd
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Toray Industries, Inc.
Umecrine AB
Vicore Pharma AB
Viking Therapeutics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xenetic Biosciences (UK) Limited
XL-protein GmbH
Yuyu Pharma, Inc.
Zafgen Inc.
Zealand Pharma A/S
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001461478/discount
List of Figures:
Number of Products under Development for Obesity, H2 2016 36
Number of Products under Development for Obesity - Comparative Analysis, H2 2016 37
Number of Products under Development by Companies, H2 2016 38
Number of Products under Investigation by Universities/Institutes, H2 2016 48
Comparative Analysis by Late Stage Development, H2 2016 51
Comparative Analysis by Clinical Stage Development, H2 2016 52
Comparative Analysis by Early Stage Products, H2 2016 53
Assessment by Monotherapy Products, H2 2016 171
Assessment by Combination Products, H2 2016 172
Number of Products by Top 10 Targets, H2 2016 173
Number of Products by Stage and Top 10 Targets, H2 2016 173
Number of Products by Top 10 Mechanism of Actions, H2 2016 181
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 181
Number of Products by Routes of Administration, H2 2016 189
Number of Products by Stage and Routes of Administration, H2 2016 189
Number of Products by Top 10 Molecule Types, H2 2016 191
Number of Products by Stage and Top 10 Molecule Types, H2 2016 191
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
